By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Cara Therapeutics, Inc. 

One Parrott Drive

Shelton  Connecticut  06484  U.S.A.
Phone: 203-567-1500 Fax: 203-567-1510


SEARCH JOBS

Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated activity in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.

CR845 is a peripherally acting kappa opioid receptor agonist currently in development for the treatment of acute and chronic pain and pruritus. In multiple randomized, double-blind, placebo-controlled Phase 2 trials in patients undergoing laparoscopic hysterectomy or bunionectomy procedures, I.V. CR845 treatment resulted in statistically significant reductions in both pain intensity and opioid-related side effects. In more than 440 subjects dosed to date, I.V. CR845 was observed to be well tolerated, without incurring the dysphoric and psychotomimetic side effects that have been reported with centrally acting (CNS-active) kappa opioid receptor agonists. Cara recently initiated its Phase 3 program with I.V. CR845 in postoperative pain. Cara also has an ongoing Phase 2 trial of an oral tablet formulation of CR845, for the treatment of osteoarthritis (OA).


Key Statistics


Email: info@caratherapeutics.com
Ownership: Public

Web Site: Cara Therapeutics
Employees:
Symbol: CARA
 









Company News
Cara Therapeutics (CARA) Reports Second Quarter 2017 Financial Results 8/4/2017 11:52:20 AM
Cara Therapeutics (CARA) Could Be 1 Clinical Trial Away From a $1 Billion Valuation 8/4/2017 6:50:07 AM
Cara Therapeutics (CARA) Appoints Mani Mohindru, Ph.D., Chief Financial Officer 8/1/2017 12:24:58 PM
Cara Therapeutics (CARA) To Announce Second Quarter 2017 Financial Results On August 3, 2017 7/28/2017 10:21:07 AM
Cara Therapeutics (CARA) Announces Summary Data From Phase I Trial Of Oral CR845 In Hemodialysis Patients With Chronic Kidney Disease 7/12/2017 10:38:46 AM
Mixed Phase II Osteoarthritis Data Sends Cara Therapeutics (CARA)' Stock Plunging 6/30/2017 5:38:18 AM
FDA Calls Cara Therapeutics (CARA)' Kidney Disease Drug a Breakthrough, Stock Soars 6/23/2017 5:50:34 AM
Cara Therapeutics (CARA) Reports Continuation Of Phase III Trial Of I.V. CR845 In Postoperative Pain Following Interim Assessment 6/21/2017 7:38:44 AM
Cara Therapeutics (CARA): A Look At The Next Catalyst—Osteoarthritis 5/16/2017 7:20:45 AM
Cara Therapeutics (CARA) Reports First Quarter 2017 Financial Results 5/5/2017 11:26:03 AM
12345678910
//-->